• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
【24h】

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

机译：Tiagabine用于治疗广泛性焦虑症：一项以帕罗西汀为阳性对照的随机，开放标签，临床试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Gamma-aminobutyric acid (GABA) plays a central role in the pathophysiology of anxiety. Tiagabine, a selective GABA reuptake inhibitor, enhances normal GABA tone. This 10-week, randomized, open-label trial evaluated tiagabine in patients with generalized anxiety disorder (GAD), with paroxetine serving as a positive control. METHOD: Adult patients with DSM-IV GAD were randomly assigned to receive either tiagabine or paroxetine. Tiagabine was initiated at 4 mg/day (2 mg morning and evening) during week 1. Between weeks 2 and 6, the dose was individually titrated in 2-mg increments (maximum increase of 4 mg/week) for optimal response to a maximum dose of 16 mg/day (8 mg morning and evening). During weeks 7 through 10, patients received the dosage determined during the titration period. Paroxetine was initiated at 20 mg nightly for the first week and similarly titrated in 10-mg increments to a maximum dose of 60 mg/day. Assessments included the Hamilton Rating Scale for Anxiety (HAM-A), HospitalAnxiety and Depression Scale (HADS), Hamilton Rating Scale for Depression (HAM-D), Pittsburgh Sleep Quality Index (PSQI), and Sheehan Disability Scale (SDS). RESULTS: Forty patients were enrolled (tiagabine, N = 20; paroxetine, N = 20). Mean final doses were tiagabine 10 mg/day (range, 4-16 mg/day) or paroxetine 27 mg/day (range, 20-40 mg/day). Tiagabine and paroxetine significantly reduced anxiety (HAM-A and HADS total and anxiety subscales). Although patients were not diagnosed with a mood disorder, both tiagabine and paroxetine reduced comorbid depressive symptoms (HAM-D total and HADS total and depressive subscale). Tiagabine and paroxetine significantly improved sleep quality (PSQI) and functioning (SDS). Both tiagabine and paroxetine were well tolerated. CONCLUSION: The selective GABA reuptake inhibitor tiagabine and the positive control paroxetine significantly reduced anxiety and comorbid depressive symptoms, improved sleep quality and functioning, and were well tolerated in patients with GAD. Tiagabine may be a therapeutic option for the treatment of anxiety disorders.
机译：背景：γ-氨基丁酸（GABA）在焦虑的病理生理中起着重要作用。替加宾是一种选择性的GABA再摄取抑制剂，可增强正常的GABA音调。这项为期10周，随机，开放标签的试验评估了泛型焦虑症（GAD）患者中的替加比滨，帕罗西汀为阳性对照。方法：DSM-IV GAD成人患者被随机分配接受替加滨或帕罗西汀治疗。在第1周内开始以4 mg / day（早晨和晚上2 mg）开始使用Tiagabine，在第2周和第6周之间，以2 mg增量（最大增加4 mg /周）分别滴定剂量，以实现对最大剂量的最佳反应剂量为16毫克/天（早晚各8毫克）。在第7至10周内，患者接受了在滴定期间确定的剂量。在第一周，帕罗西汀的起始剂量为每晚20 mg，并以10 mg的增量逐渐滴定至最大剂量60 mg / day。评估包括汉密尔顿焦虑量表（HAM-A），医院焦虑和抑郁量表（HADS），汉密尔顿抑郁量表（HAM-D），匹兹堡睡眠质量指数（PSQI）和希恩残疾量表（SDS）。结果：40名患者入组（替加滨，N = 20;帕罗西汀，N = 20）。平均最终剂量为tiagabine 10 mg /天（范围4-16 mg /天）或paroxetine 27 mg /天（范围20-40 mg /天）。替加宾和帕罗西汀可显着减少焦虑（HAM-A和HADS总和焦虑量表）。尽管未诊断出患有情绪障碍的患者，但替加滨和帕罗西汀均减轻了合并症的抑郁症状（HAM-D总数和HADS总数以及抑郁量表）。替加宾和帕罗西汀可显着改善睡眠质量（PSQI）和功能（SDS）。替加滨和帕罗西汀均耐受良好。结论：GAD患者选择性GABA再摄取抑制剂替加宾和阳性对照帕罗西汀可显着降低焦虑和合并抑郁症状，改善睡眠质量和功能，并具有良好的耐受性。 Tiagabine可能是治疗焦虑症的一种治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号